News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Phalanx Labs Banned from Shipping Products to U.S. After Refusing Inspection
June 21, 2016
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
The US FDA has banned Phalanx Labs from shipping products to the US after the Indian API and intermediates firm refused to let inspectors visit its site in Visakhapatnam.
Twitter
LinkedIn
Facebook
Email
Print
Asia
MORE ON THIS TOPIC
Obesity
Kailera, Hengrui Push Oral GLP-1/GIP Pill to Phase 3 After Clearing Mid-Stage China Study
February 10, 2026
·
1 min read
·
Tristan Manalac
China
Clinical Trials Are Increasingly Going Global—With China a Main Beneficiary
February 2, 2026
·
8 min read
·
Annalee Armstrong
Obesity
AstraZeneca’s China Trip Yields CSPC Obesity Deal Worth $1.2B Upfront
January 30, 2026
·
2 min read
·
Tristan Manalac
China
AstraZeneca Pledges $15B More in Chinese Investments for Cell Therapies, Radiopharma
January 29, 2026
·
1 min read
·
Tristan Manalac
